Suscribirse

Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma - 17/08/11

Doi : 10.1016/j.jaci.2006.02.047 
Chih-Lung Chen, PhD a, c, , Shulhn-Der Wang, MD b, , Zhao-Ying Zeng, BSc c, Kuo-Juei Lin, MD d, Shung-Te Kao, MD, PhD a, Thoru Tani, MD e, Chun-Keung Yu, PhD c, Jiu-Yao Wang, MD, DPhil c, f,
a From the Division of Biomaterial and Tissue Engineering, Industrial Technology Research Institute, Hsing-Chu 
b Institute of Chinese Medical Science, China Medical University, Taichung 
c Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 
d Institute of Chinese and Western Medical Science, China Medical University, Taichung 
e Department of Surgery, Shiga University of Medical Science, Shiga 
f Department of Pediatrics, College of Medicine, National Cheng Kung University, Tainan 

Reprint requests: Jiu-Yao Wang, MD, DPhil, Department of Pediatrics, College of Medicine, National Cheng Kung University, No 138, Sheng-Li Road, Tainan, 70101 Taiwan.

Hsing-Chu, Taichung, and Tainan, Taiwan, and Shiga, Japan

Abstract

Background

Serine proteases such as mast cell tryptase and certain allergens are important in the pathogenesis of allergic inflammation of asthma.

Objective

We sought to investigate the effects of serine protease inhibitors nafamostat mesilate (FUT), gabexate mesilate (FOY), and ulinastatin (UTI) on airway inflammation in a mouse model of allergic asthma.

Methods

BALB/c mice were sensitized to Dermatophagoides pteronyssinus (Der p) and intratracheally challenged with Der p (0.5 mg/mL). Therapeutic doses of FUT (0.0625 mg/kg), FOY (20 mg/kg), and UTI (10,000 U/kg) were intra-peritoneally injected into 3 corresponding sensitized mice during the sensitization phase (protocol 1) or 24 hours after allergen challenge (protocol 2).

Results

Both FUT-treated and FOY-treated sensitized mice had reduced mast cells activation, airway hyperresponsiveness, attenuated eosinophils infiltrations, and decreased Der p–induced IL-4 and TNF-⍺, but increased IL-12 cytokine production in bronchoalveolar lavage fluid compared with nontreated mice. Furthermore, FUT treatment downregulated the expression of IL-1β, TNF-⍺, IL-6, eotaxin, inducible NO synthase, CD86, and nuclear factor-κB activation, but enhanced the expression of IL-12 and IL-10 in Der p–stimulated alveolar macrophages. UTI-treated mice have no significant change of the aforementioned measurements compared with nontreated sensitized mice.

Conclusion

Nafamostat mesilate and FOY exerting the therapeutic effect in allergen-induced airway inflammation was a result not only of their inhibitory action in the early phase of mast cells activation but also of immunoregulatory function in the late phase of allergic inflammation. Such properties of FUT and FOY might be a potential therapeutic approach for asthma.

Clinical implications

The clinical used of serine protease inhibitors FUT and FOY may also have implications for treating airway inflammation of asthma.

El texto completo de este artículo está disponible en PDF.

Key words : Serine protease inhibitor, allergy, airway inflammation, eosinophils

Abbreviations used : AHR, AM, BAL, BALF, FOY, FUT, iNOS, i.t., mMCP-1, NF-κB, Penh, UTI


Esquema


 Supported by grant NSC89-2320-B006-029 and the National Science Council, Taiwan, Republic of China.
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.


© 2006  American Academy of Allergy, Asthma and Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 118 - N° 1

P. 105-112 - juillet 2006 Regresar al número
Artículo precedente Artículo precedente
  • Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals
  • Go Takayama, Kazuhiko Arima, Taisuke Kanaji, Shuji Toda, Hiroyuki Tanaka, Shunsuke Shoji, Andrew N.J. McKenzie, Hiroichi Nagai, Takao Hotokebuchi, Kenji Izuhara
| Artículo siguiente Artículo siguiente
  • Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism
  • Anick Langlois, Claudine Ferland, Guy M. Tremblay, Michel Laviolette

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.